glp-1 drugs market dynamics 2025 Diabetes Treatment | Global Market Analysis Report GLP-1 trends 2025: real-world data,
Description
The biotech firm Metsera, which is developing a once-monthly GLP-1 injection, became the object of a bidding war between Pfizer and Novo Nordisk, with Pfizer emerging as the winner
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial
Whats the difference between the GLP-1s on the market
While GLP-1 is mainly expressed and translated in intestinal L cells
Compounded semaglutide and tirzepatide Compounded versions of semaglutide and tirzepatide represent one of the most popular alternatives to brand-name medications
